Compare BigBearai Holdings Inc (BBAI) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs ClearPoint Neuro Inc — how do they compare? BigBearai Holdings Inc trades at $3.12 (market cap $1.48B), while ClearPoint Neuro Inc trades at $16.07 (market cap $478.63M). The key difference: BigBearai Holdings Inc is far larger — about 3.1× ClearPoint Neuro Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | CLPT | |
|---|---|---|
Market Cap | $1.48B | $478.63M |
Sector | Technology | Health |
52-Week High | $8.91 | $29.60 |
52-Week Low | $3.05 | $8.66 |
Enterprise Value | $1.16B | $506.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.08, down 5.81% in the past 24 hours, with a bearish technical signal from moving averages. The company reported revenue of $127.67M in 2025 but a net loss of $293.91M, reflecting a negative net margin of -226.69%. Recent news highlights AI growth opportunities in defense and airport security, yet profitability challenges persist.
Outlook remains cautious due to ongoing losses and negative cash flow from operations. Investment opportunities include backlog growth and debt reduction, but risks include high SG&A expenses and reliance on government contracts. Analyst consensus is mixed with 75% hold ratings, indicating uncertainty about near-term performance.
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
